Aclaris Therapeutics/ACRS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Aclaris Therapeutics

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.

Ticker

ACRS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Neal Walker

Employees

91

Headquarters

Wayne, United States

ACRS Metrics

BasicAdvanced
$73M
Market cap
-
P/E ratio
-$1.09
EPS
0.07
Beta
-
Dividend rate
$73M
0.0701
$11.12
$0.59
804K
6.74
-38.27%
-48.47%
-42.29%
2.359
0.517
0.517
0.95%
24.52%
68.93%

What the Analysts think about ACRS

Analyst Ratings

Majority rating from 9 analysts.
Hold

ACRS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-734.78% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.3M
-86.86%
Net income
-$17M
1,107.14%
Profit margin
-734.78%
9,084.75%

ACRS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 16.00%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.42
-$0.41
-$0.02
-$0.24
-
Expected
-$0.45
-$0.48
-$0.34
-$0.29
-$0.20
Surprise
-6.67%
-14.58%
-94.19%
-16.00%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Aclaris Therapeutics stock?

Aclaris Therapeutics (ACRS) has a market cap of $73M as of June 17, 2024.

What is the P/E ratio for Aclaris Therapeutics stock?

The price to earnings (P/E) ratio for Aclaris Therapeutics (ACRS) stock is 0 as of June 17, 2024.

Does Aclaris Therapeutics stock pay dividends?

No, Aclaris Therapeutics (ACRS) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next Aclaris Therapeutics dividend payment date?

Aclaris Therapeutics (ACRS) stock does not pay dividends to its shareholders.

What is the beta indicator for Aclaris Therapeutics?

Aclaris Therapeutics (ACRS) has a beta rating of 0.07. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Aclaris Therapeutics stock price target?

The target price for Aclaris Therapeutics (ACRS) stock is $1.84, which is NaN% below the current price of $. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Aclaris Therapeutics stock

Buy or sell Aclaris Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing